EMA (EU)
EVENT
Committee for Orphan Medicinal Products (COMP): 8-10 September 2026
Published: 9/10/2026Detected: 7/18/2026
Summary preview
Schedules the COMP meeting (8–10 September 2026) at the European Medicines Agency in Amsterdam to support review of applications for orphan medicinal product designation for rare-disease medicines.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
clinical
safety
quality
labeling
manufacturing
#COMP
#orphan medicinal product designation
#rare diseases
#EMA
#designation application
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026